Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Perspective Therapeutics, Inc.

< Previous 1 2 Next >
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate in Upcoming May Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Present at Upcoming March Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
From Perspective Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.